Cargando…
Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes
PURPOSE: Cardiovascular mortality remains high among patients with diabetes compared with the general population. The primary aim was to evaluate the interest in and demand for advanced cardiovascular screening in patients with diabetes; the secondary aim was to explore its efficiency in detecting u...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221412/ https://www.ncbi.nlm.nih.gov/pubmed/32440223 http://dx.doi.org/10.2147/CLEP.S246636 |
_version_ | 1783533360060039168 |
---|---|
author | Lindholt, Jes Sanddal Frystyk, Jan Hallas, Jesper Rasmussen, Lars Melholt Diederichsen, Axel Cosmus Pyndt |
author_facet | Lindholt, Jes Sanddal Frystyk, Jan Hallas, Jesper Rasmussen, Lars Melholt Diederichsen, Axel Cosmus Pyndt |
author_sort | Lindholt, Jes Sanddal |
collection | PubMed |
description | PURPOSE: Cardiovascular mortality remains high among patients with diabetes compared with the general population. The primary aim was to evaluate the interest in and demand for advanced cardiovascular screening in patients with diabetes; the secondary aim was to explore its efficiency in detecting unprotected subclinical cardiovascular disease (CVD). PATIENTS AND METHODS: In a cross-sectional design, randomly selected 40–60-year-old men and women with diabetes were invited to the screening trial. Screening encompassed (1) a comprehensive medical interview; (2) non-contrast computed tomography scanning to quantify coronary artery and aortic valve calcification, to measure left atrial size, to assess heart rhythm and to detect aortic and iliac dilatations; (3) ankle and brachial blood pressure measurements; and (4) blood and urine samples for measurements of HbA(1c), lipid profile, renal function, NT-pro B-type natriuretic peptide (pro-BNP) and albuminuria. Primary outcome was participation rate; secondary outcome was rate of unprotected subclinical CVD. RESULTS: Of 465 invited patients, 191 (41.1%) attended screening. The participation rate was 40% (95% CI:33–47) for males and 42% (95% CI:36–48) for females. Twenty-four patients were excluded due to previous CVD. The remaining patients’ mean age was 52 years; 58% were males. Subclinical CVD was found in 64%, with a male preponderance (males 75% (95% CI:66–83; females 49% (95% CI:37–60)). Presence of severe coronary artery calcification (score ≥ 400) showed a male preponderance (males 19% (95% CI:12–27); females 7% (95% CI:3–16)). Aortic valve calcification, enlarged left atrial volume, atrial fibrillation, aortic dilatations, peripheral artery disease or increased pro-BNP were uncommon, and without any sex differences. Unprotected subclinical CVD was very common, and medical treatment was intensified in 60% (95% CI:53–68) of patients. CONCLUSION: We propose a feasible cardiovascular screening examination from which middle-aged patients with diabetes may benefit. However, the participation rate may be too low to warrant screening. |
format | Online Article Text |
id | pubmed-7221412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72214122020-05-21 Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes Lindholt, Jes Sanddal Frystyk, Jan Hallas, Jesper Rasmussen, Lars Melholt Diederichsen, Axel Cosmus Pyndt Clin Epidemiol Original Research PURPOSE: Cardiovascular mortality remains high among patients with diabetes compared with the general population. The primary aim was to evaluate the interest in and demand for advanced cardiovascular screening in patients with diabetes; the secondary aim was to explore its efficiency in detecting unprotected subclinical cardiovascular disease (CVD). PATIENTS AND METHODS: In a cross-sectional design, randomly selected 40–60-year-old men and women with diabetes were invited to the screening trial. Screening encompassed (1) a comprehensive medical interview; (2) non-contrast computed tomography scanning to quantify coronary artery and aortic valve calcification, to measure left atrial size, to assess heart rhythm and to detect aortic and iliac dilatations; (3) ankle and brachial blood pressure measurements; and (4) blood and urine samples for measurements of HbA(1c), lipid profile, renal function, NT-pro B-type natriuretic peptide (pro-BNP) and albuminuria. Primary outcome was participation rate; secondary outcome was rate of unprotected subclinical CVD. RESULTS: Of 465 invited patients, 191 (41.1%) attended screening. The participation rate was 40% (95% CI:33–47) for males and 42% (95% CI:36–48) for females. Twenty-four patients were excluded due to previous CVD. The remaining patients’ mean age was 52 years; 58% were males. Subclinical CVD was found in 64%, with a male preponderance (males 75% (95% CI:66–83; females 49% (95% CI:37–60)). Presence of severe coronary artery calcification (score ≥ 400) showed a male preponderance (males 19% (95% CI:12–27); females 7% (95% CI:3–16)). Aortic valve calcification, enlarged left atrial volume, atrial fibrillation, aortic dilatations, peripheral artery disease or increased pro-BNP were uncommon, and without any sex differences. Unprotected subclinical CVD was very common, and medical treatment was intensified in 60% (95% CI:53–68) of patients. CONCLUSION: We propose a feasible cardiovascular screening examination from which middle-aged patients with diabetes may benefit. However, the participation rate may be too low to warrant screening. Dove 2020-05-06 /pmc/articles/PMC7221412/ /pubmed/32440223 http://dx.doi.org/10.2147/CLEP.S246636 Text en © 2020 Lindholt et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lindholt, Jes Sanddal Frystyk, Jan Hallas, Jesper Rasmussen, Lars Melholt Diederichsen, Axel Cosmus Pyndt Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title | Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title_full | Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title_fullStr | Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title_full_unstemmed | Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title_short | Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes |
title_sort | feasibility study of advanced cardiovascular screening in middle-aged patients with diabetes |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221412/ https://www.ncbi.nlm.nih.gov/pubmed/32440223 http://dx.doi.org/10.2147/CLEP.S246636 |
work_keys_str_mv | AT lindholtjessanddal feasibilitystudyofadvancedcardiovascularscreeninginmiddleagedpatientswithdiabetes AT frystykjan feasibilitystudyofadvancedcardiovascularscreeninginmiddleagedpatientswithdiabetes AT hallasjesper feasibilitystudyofadvancedcardiovascularscreeninginmiddleagedpatientswithdiabetes AT rasmussenlarsmelholt feasibilitystudyofadvancedcardiovascularscreeninginmiddleagedpatientswithdiabetes AT diederichsenaxelcosmuspyndt feasibilitystudyofadvancedcardiovascularscreeninginmiddleagedpatientswithdiabetes |